TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05891080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
Study: NCT05733949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo ST-SBRT
Study: NCT04973202

Intervention type: OTHER
Intervention: Stay for alcohol detoxification
Description: Stay for alcohol detoxification : routine care.
Study: NCT05822947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active manual therapy
Description: Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control manual therapy
Description: Light touch and a breathing exercise (3 to 4 minutes).
Study: NCT05973500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Mediterranean Diet for 42 Days
Study: NCT06159530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implants
Description: 4 dental implants placed in the mandible according to all-on 4 concept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implants
Description: 4 dental implants placed in the mandible according to all-on 4 concept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peek framework
Description: peek framework screwed to multi-unit abutments of 4-implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peek framework
Description: peek framework screwed to multi-unit abutments of 4-implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visio-lign nano composite
Description: peek framework veneered with nano composite (visio-lign) as an occlusal material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zirconia crowns
Description: peek framework covered with zirconia crowns as an occlusal material
Study: NCT05746312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healing attempt
Description: The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
Study: NCT05013073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMAXcel ED Application
Description: A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
Study: NCT03229850

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin lispro
Description: Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin lispro
Description: Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
Study: NCT05544357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short set configuration resistance training
Description: Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short set configuration resistance training
Description: Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long set configuration resistance training
Description: Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long set configuration resistance training
Description: Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
Study: NCT05114720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard adjuvant chemotherapy plus moxifloxacin
Description: docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard adjuvant chemotherapy plus placebo
Description: docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
Study: NCT05990114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The structured caregiver support program
Description: It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
Study: NCT06231160

Intervention type: PROCEDURE
Intervention: Systematic Therapy Combined With Microwave Ablation
Description: Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
Study: NCT04740788

Intervention type: DEVICE
Intervention: Monofocal IOL
Description: Patients are already implanted with a monofocal lens
Study: NCT06436508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol
Description: * Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
Study: NCT05942872

Intervention type: OTHER
Intervention: This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
Description: This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
Study: NCT06066658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cranial electrotherapy stimulation (Alpha-Stim AID)
Description: Alpha-Stim AID
Study: NCT04970797

Intervention type: DRUG
Intervention: Xinglouchengqi decoction
Description: the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
Study: NCT06139445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo Group
Description: random superficial touches not involved in any manual technique
Study: NCT05590013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pectointercostal and ESP block
Description: Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pectointercostal and ESP block
Description: Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
Study: NCT05333289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1030
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1030
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1030
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1020
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1020
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1020
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Sterile liquid for injection
Study: NCT05765604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant vaccine(Sf9 cell)
Description: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine(CHO cell)
Description: IM
Study: NCT05048784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral tablet
Study: NCT06280170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence platform for case managers
Description: Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
Study: NCT05593120

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-FFR
Description: In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine care
Description: All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
Study: NCT06433869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rmhTNF-NC
Description: Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rmhTNF-NC
Description: Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
Study: NCT05447715

Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
Study: NCT04831892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal
Description: Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizer containing Colloidal Oatmeal only
Description: Vehicle lotion containing 0.1% colloidal oatmeal.
Study: NCT05909462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
Description: ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
Description: ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
Study: NCT05613192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
Study: NCT05155410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exogenous Ketone Monoester
Description: Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
Study: NCT05148559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder Sent Via Preferred Method of Communication
Description: Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reminder Sent Via Mailed Letter
Description: Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
Study: NCT06283303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011 hepatic artery infusion
Description: The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
Study: NCT05141565

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04873895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib 5 MG
Description: axitinib 5 mg po BID until progression or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pill
Description: hydroxychloroquine 600 mg po BID until progression or intolerance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans arterial chemoembolization
Description: segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
Study: NCT04788004

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.
Study: NCT06258356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: novel ultra-short-acting benzodiazepine-like anesthetic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline (compared to Remimazolam)
Study: NCT05954806

Intervention type: DRUG
Intervention: Antivenom Snakes
Description: No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
Study: NCT05496257

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct pulp capping in primary molars
Description: caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct pulp capping in primary molars
Description: caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
Study: NCT05392010

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05114798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
Study: NCT05576870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based toddler nutrition
Description: Plant based toddler nutrition fed daily ad libitum

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy based toddler nutrition
Description: Commercially available toddler nutrition fed daily ad libitum
Study: NCT06293495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma 3 Nail (Stryker)
Description: Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chimaera Nail (Orthofix)
Description: Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
Study: NCT04902794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Emitting Diode
Description: Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Light Emitting Diode
Description: Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
Study: NCT03803397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PV-001-DC
Description: Patient-specific cellular therapeutic for cancer immunotherapy
Study: NCT05826795

Intervention type: PROCEDURE
Intervention: Early goal-directed therapy (EGDT)
Description: The principle of hemodynamic optimization to achieve the defined goals.